课题基金 / 基金详情

TRIAL OF PFHUK5 IL 2 IMMUNOCYTOKINE FUSION IN PROSTATE CARCINOMA

TRIAL OF PFHUK5 IL 2 IMMUNOCYTOKINE FUSION IN PROSTATE CARCINOMA
PFHUK5 IL 2 免疫细胞因子融合在前列腺癌中的试验
批准号：
6265434
负责人：
GLENN J BUBLEY
金额：
$2.98万
依托单位：
BETH ISRAEL DEACONESS MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6265434
关键词：
chimeric proteins clinical research clinical trial phase I cytokine dosage drug adverse effect drug screening /evaluation human subject human therapy evaluation interleukin 2 neoplasm /cancer immunotherapy pharmacokinetics prostate neoplasms

项目摘要

项目成果

GLENN J BUBLEY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
To assess the toxicity and determine the maximum tolerated dose of the immunocytokine fusion protein HuKS-IL-2 when administered as 4-hour infusions daily for 3 consecutive days and to determine the pharmacokinetics of this agent.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
SEQUENTIAL HORMONAL THERAPY FOR ANDROGEN INDEPENDENT PROSTATE CANCER
SEQUENTIAL/ADDITIVE HORMONAL THERAPY FOR PROSTATE CANCER
海外基金